Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling

Anticancer Research

Volumn 35, Issue 1, 2015, Pages 39-46

  Chung, Seyung S ^a   Vadgama, Jaydutt V ^a,b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer stem cells; CD44; Curcumin; EGCG; NF B; STAT3

Indexed keywords

CURCUMIN; EPIGALLOCATECHIN GALLATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; CATECHIN; CD44 PROTEIN, HUMAN; HERMES ANTIGEN; STAT3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER STEM CELL; CELL POPULATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MCF 7 CELL LINE; PHENOTYPE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ANTIGENS, CD44; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATECHIN; CELL MOVEMENT; CURCUMIN; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MCF-7 CELLS; NEOPLASTIC STEM CELLS; NF-KAPPA B; PHENOTYPE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84920374751     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006.
3. Rathone K and Wang HC: Mesenchymal and stem-like cell targeting in suppression of chronically induced breast carcinogenesis. Cancer Lett 333: 113-123, 2013.
4. Smalley MJ and Dale TC: Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev 18: 215-230, 1999.
5. Dontu G, Jackson K W, McNicholas E, Kawamura M J, Abdallah W M and Wicha MS: Role of Notch signaling in cellfate determination of human mammary stem/progenitor cells. Breast Cancer Res 6: R605-R615, 2004.
6. Liu S, Dontu G, Mantle ID, Ahn NS, Jackson KW, Suri P, Wicha MS: Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66: 6063-6071, 2006.
7. Zhong Z, Wen Z and Darnell JE: STAT3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98, 1994.
8. Turkson J and Jove R: STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19: 6613-6626, 2000.
9. Azare J, Doane A, Leslie K, Chang Q, Berishaj M, Nnoli J, Mark K, Al-Ahmadie H, Gerald W, Hassimi M, Viale A, Stracke M, Lyden D and Bromberg J: STAT3 mediates expression of autotaxin in breast cancer. PLOS One 6: e27861, 2011.
10. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, Enkemann S, Jove R and Haura EB: STAT3 regulates genes common both wound healing and cancer. Oncogene 24: 3397-3408, 2005.
11. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB: Curcumin and cancer: an "old-age" disease with an "ageold" solution. Cancer letters 267: 133-164, 2008.
12. Yang CS, Wang X: Green tea and cancer prevention. Nutrition and cancer 62: 931-937, 2010.
13. Shureiqi I, Baron JA: Curcumin chemoprevention: the long road to clinical translation. Cancer Prev Res (Phila) 4: 296-298, 2011.
14. Lopez-Lazaro M: Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Molecular Nutrition and Food Research 52(Suppl 1): S103-S127, 2008.
15. Hsu CH and Cheng AL: Clinical studies with curcumin. Advances in Experimental Medicine and Biology. Advances in Exper Med Biol 595: 471-480, 2007.
16. Jiao Y, Wilkinson J, Di X, Wang W, Hatcher H, Kock ND, D'Agostino R Jr, Knovich MA, Torti FM and Torti SV: Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood 113: 462-469, 2009.
17. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK: Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13: 3423-3430, 2007.
18. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV: Curcumin: From ancient medicine to current clinical trials. Cellular and Molecular Life Sciences 65: 1631-1652, 2008.
19. Lambert JD and Yang CS: Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. Mutat Res 524: 201-208, 2003.
20. Yang CS, Wang X, Lu G and Picinich SC: Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nature reviews Cancer 9: 429-439, 2009.
21. Henning SM, Wang P and Heber D: Chemopreventive effects of tea in prostate cancer: green tea versus black tea. Molecular nutrition & food research 55: 905-920, 2011.
22. Yang GY, Liao J, Li C, Chung J, Yurkow EJ, Ho CT and Yang CS: Effect of black and green tea polyphenols on c-JUN phosphorylation and H(2)O(2) production in transformed and non-transformed human bronchial cell lines: possible mechanisms of cell growth inhibition and apoptosis induction. Carcinogenesis 21: 2035-2039, 2000.
23. Qiao Y, Cao J, Xie L and Shi X: Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells. Archives of Pharmacal Res 32: 1309-1315, 2009.
24. Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M: Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Research 63: 8118-8121, 2003.
25. Zhao Y, Yu L, Xu S, Qiu F, Fan Y and Fu G: Down-regulation of connexin43 gap junction by serum deprivation in human endothelial cells was improved by (-)-epigallocatechin gallate via ERK MAP kinase pathway. Biochem Biophys Res Commun 404: 217-222, 2010.
26. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gonen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA and Polyak K: The JAK2/STAT3 signaling pathway is required for growth of CD44(+) CD24(?) stem celllike breast cancer cells in human tumors. J Clin Invest 121: 2723-2735, 2011.
27. Shostak K and Chariot A: NFκB, stem cells and breast cancer: the links get stronger. Breast Cancer Res 13: 214, 2011.
28. Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM: Suppression of TNF-α-induced apotosis by NF-κB. Science 274: 787-789, 1996.
29. Huang H, Zhao W and Yang D: Stat3 induces oncogenic Skp2 expression in human cervical carcinoma cells. Biochem Biophys Res Commun 418: 186-190, 2012.
30. Darnell JE Jr.: STATs and gene regulation. Science 277: 1630-1635, 1997.
31. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE Jr.: Stat3 as an oncogene. Cell 98: 295-303, 1999.
32. Fukada T, Ohtani T, Yoshida Y, Shirogane T, Nishida K, Nakajima K Hibi M, Hirano T: STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J 17: 6670-6677, 1998.
33. Sherry MM, Reeves A, Wu JK and Cochran BH: STAT3 is required for proliferation and maintenance of multipotency of glioblastoma stem cells. Stem Cells 27: 2383-2392, 2009.
34. Assimakopoulos D, Kolettas E, Patrikakos G and Evangelou A: The role of CD44 in the development and prognosis of head and neck squamous cell carcinomas. Histol. Histopathol 17: 1269-1281, 2002.
35. Bourguignon LY, Singleton PA, Zhu H and Diedrich F: Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem 278: 29420-29434, 2003.